Pardes Biosciences nets $199 million in COVID-19 pill race
The Carlsbad startup is in early clinical trials for an experimental antiviral oral treatment for COVID-19, akin to Tamiflu for influenza.
Source: latimes.com
Page 2 - Fs Development Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Fs Development Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Fs Development Corp Today - Breaking & Trending Today
Newly public Pardes Bio aims to show its Covid-19 pill can offer edge over Pfizer's
Pardes Biosciences’ experimental oral antiviral for treating and preventing Covid-19 infection addresses the same target as Pfizer’s authorized pill Paxlovid, but with a potential dosing advantage. The Pardes pill is in Phase 1 testing, and the biotech joined the public markets this week after completing a SPAC merger that infuses the company with $274 million.
Source: medcitynews.com
Carlsbad's Pardes Biosciences nets $199M in SPAC deal to keep pace in the COVID-19 pill race
Startup is in early clinical trials for an experimental antiviral oral treatment for COVID-19, akin to Tamiflu for influenza.
Source: sandiegouniontribune.com
Pardes to go public, says Covid-19 antiviral pill does not need booster
Pardes Biosciences on Tuesday said early human testing shows that its experimental Covid-19 antiviral pill works as a standalone treatment and announced plans to go public by merging with a special purpose acquisition company. If the drug, called PBI-0451, proves effective in later-stage testing, it could have an advantage over similar pills that need to be taken with a
Source: deccanherald.com
Pardes to go public, says Covid-19 antiviral pill does not need booster
Pardes Biosciences on Tuesday said early human testing shows that its experimental COVID 19 antiviral pill works as a standalone treatment and announc...
Source: thepeninsulaqatar.com